Ongoing research is exploring various aspects of thioguanine therapy, including optimizing dosing regimens based on genetic testing for TPMT polymorphisms. Studies are also investigating novel formulations and combinations with other chemotherapeutic agents to enhance efficacy while minimizing toxicity.
In conclusion, thioguanine remains a critical drug in the cancer treatment arsenal, but its use requires careful consideration of its toxicological profile. Understanding its metabolism, potential adverse effects, and patient-specific factors is essential in maximizing therapeutic outcomes while minimizing risks.
